A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.

Journal of the Advanced Practitioner in Oncology
Donald C Moore, Daniel Thompson

Abstract

The B-cell receptor signaling pathway plays an integral role in the proliferation and survival of malignant B cells. Targeting the B-cell receptor pathway via the inhibition of Bruton tyrosine kinase (BTK) has evolved the treatment of a variety of B-cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenström macroglobulinemia. Currently, there are three BTK inhibitors approved by the U.S. Food and Drug Administration: ibrutinib, acalabrutinib, and zanubrutinib. This article reviews the pharmacology, clinical efficacy, safety, dosing, drug-drug interactions, and implications for advanced practitioners of BTK inhibitors in the treatment of B-cell malignancies.

Software Mentioned

RESONATE
ELEVATE
TN
iLLUMINATE

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Anti-cancer Agents in Medicinal Chemistry
Alessandro GozzettiMonica Bocchia
Clinical Advances in Hematology & Oncology : H&O
Jan A Berger
© 2021 Meta ULC. All rights reserved